In: Bazer FW, Lamb GC, Wu G (eds) Animal agriculture: challenges, innovations, and sustainability
Therapeutic implications: modulating nodes, not just scavenging Therapy should target network nodes and compartments, not just mop up oxidants: indiscriminate antioxidant loading can blunt adaptive signalling and leave the upstream drivers untouched, whereas node-specific, compartment-aware strategies act where the chemistry originates and where signals are decoded
PubMed CrossRef Sutar R, Kumar A, Yadav V
Future GLP-1 trends: new drugs and therapies on the horizon The future of weight management may soon involve more than current GLP-1s: Amylin mimetics: These compounds mimic another satiety hormone and may complement GLP-1s. Mazdutide: A dual glucagon/GLP-1 agonist showing strong Phase 3 results and promising greater weight loss. Oral GLP-1s: Pills in development could improve convenience. Muscle-preserving combinations: Researchers are exploring co-therapies to prevent loss of lean mass during weight loss. Providers should prepare for a rapidly evolving landscape and educate patients about upcoming options. Key takeaways on GLP-1 trends for providers and patients Efficacy varies across drugs and doses
A CV benefit in this trial may indicate the need for earlier intervention in CV risk reduction, even before the development of T2D
